PIK3CA and metastatic neoplasm: The ability of PI3K inhibitors to impact PDAC cells regardless of their genetic/epigenetic landscape make PI3K an ideal pharmacological target for PDAC patients, and further makes the case for the prognostic potential of PI3Kα activity signature in the detection of micro‐metastatic disease.